ALS Research Group

Umeå University Hospital

The ALS research group at Umeå University Hospital performs clinical studies, including phase 1—3 trials as well as molecular pathology research using genetic (DNA), proteomic (proteins) and metabolomic approaches.

UmeaUniversity_Logo
Umeå University Hospital

In 1992, the ALS Clinical Center was established at Umeå University Hospital. This is now the principal center for diagnosing and caring of patients with neuromuscular diseases in northern Sweden. The clinical team also performs second-opinion evaluations of patients from other parts of Sweden and from abroad. Since 1992 the center has conducted clinical phase 1—3 trials which concern investigator initiated clinical trials as well as studies with the industry. The ALS Clinical Center is part of the larger ALS Research Consortium in Umeå that also performs genetic, histopathology and molecular-pathology studies. The focus is on studying SOD1 and its role as a prion in causing cell death.

Contact
Location
Umeå University, Postadress:, Umeå, Sweden

Our Specialists

Peter Andersen

Professor of Neurology and Senior Neurologist

Professor Andersen obtained his medical degree from Copenhagen University and specialised in […]

Peter Andersen
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more